BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21905596)

  • 41. Randomized, double-blind study of the clinical efficacy of 3 days of azithromycin compared with co-amoxiclav for the treatment of acute otitis media.
    Dunne MW; Latiolais T; Lewis B; Pistorius B; Bottenfield G; Moore WH; Garrett A; Stewart TD; Aoki J; Spiegel C; Boettger D; Shemer A
    J Antimicrob Chemother; 2003 Sep; 52(3):469-72. PubMed ID: 12888586
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term azithromycin therapy to reduce acute exacerbations in patients with severe chronic obstructive pulmonary disease.
    Naderi N; Assayag D; Mostafavi-Pour-Manshadi SM; Kaddaha Z; Joubert A; Ouellet I; Drouin I; Li PZ; Bourbeau J
    Respir Med; 2018 May; 138():129-136. PubMed ID: 29724384
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antibiotics against Pseudomonas aeruginosa for COPD exacerbation in ICU: a 10-year retrospective study.
    Planquette B; Péron J; Dubuisson E; Roujansky A; Laurent V; Le Monnier A; Legriel S; Ferre A; Bruneel F; Chiles PG; Bedos JP
    Int J Chron Obstruct Pulmon Dis; 2015; 10():379-88. PubMed ID: 25733827
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Bacterial pathogens in sputum and degree of bronchial obstruction in patients with acute exacerbation of chronic obstructive pulmonary disease].
    Biagini M; Rossi M
    Recenti Prog Med; 2002 Sep; 93(9):470-3. PubMed ID: 12355983
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A prospective study on bacterial and atypical etiology of acute exacerbation in chronic obstructive pulmonary disease.
    Nakou A; Papaparaskevas J; Diamantea F; Skarmoutsou N; Polychronopoulos V; Tsakris A
    Future Microbiol; 2014; 9(11):1251-60. PubMed ID: 25437187
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An open label, randomized comparative study of levofloxacin and amoxicillin/clavulanic acid in the treatment of purulent sinusitis in adult Thai patients.
    Jareoncharsri P; Bunnag C; Fooanant S; Tunsuriyawong P; Voraprayoon S; Srifuengfung S; Dhiraputra C
    Rhinology; 2004 Mar; 42(1):23-9. PubMed ID: 15072030
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibiotic use in patients admitted with acute exacerbations of chronic obstructive pulmonary disease.
    Smith JA; Redman P; Woodhead MA
    Eur Respir J; 1999 Apr; 13(4):835-8. PubMed ID: 10362049
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations.
    Patel IS; Seemungal TA; Wilks M; Lloyd-Owen SJ; Donaldson GC; Wedzicha JA
    Thorax; 2002 Sep; 57(9):759-64. PubMed ID: 12200518
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bacterial infections in patients requiring admission for an acute exacerbation of COPD; a 1-year prospective study.
    Groenewegen KH; Wouters EF
    Respir Med; 2003 Jul; 97(7):770-7. PubMed ID: 12854626
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibiotics for treatment and prevention of exacerbations of chronic obstructive pulmonary disease.
    Wilson R; Sethi S; Anzueto A; Miravitlles M
    J Infect; 2013 Dec; 67(6):497-515. PubMed ID: 23973659
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antibiotic therapy for exacerbations of chronic obstructive pulmonary disease (COPD).
    Butorac-Petanjek B; Parnham MJ; Popovic-Grle S
    J Chemother; 2010 Oct; 22(5):291-7. PubMed ID: 21123150
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease.
    Daniels JM; Snijders D; de Graaff CS; Vlaspolder F; Jansen HM; Boersma WG
    Am J Respir Crit Care Med; 2010 Jan; 181(2):150-7. PubMed ID: 19875685
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of cefixime or co-amoxiclav treatment on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media.
    Dabernat H; Geslin P; Megraud F; Bégué P; Boulesteix J; Dubreuil C; de La Roque F; Trinh A; Scheimberg A
    J Antimicrob Chemother; 1998 Feb; 41(2):253-8. PubMed ID: 9533468
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The role of macrolides in treatment of exacerbations of chronic obstructive pulmonary disease].
    Targowski T; Jahnz-Rózyk K
    Pol Merkur Lekarski; 2010 Apr; 28(166):311-4. PubMed ID: 20491344
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice.
    Sachs AP; Koëter GH; Groenier KH; van der Waaij D; Schiphuis J; Meyboom-de Jong B
    Thorax; 1995 Jul; 50(7):758-63. PubMed ID: 7570411
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin.
    Hoogkamp-Korstanje JA; Dirks-Go SI; Kabel P; Manson WL; Stobberingh EE; Vreede RW; Davies BI
    J Antimicrob Chemother; 1997 Mar; 39(3):411-4. PubMed ID: 9096192
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Sputum Microbiome in Chronic Obstructive Pulmonary Disease Exacerbations.
    Huang YJ; Boushey HA
    Ann Am Thorac Soc; 2015 Nov; 12 Suppl 2(Suppl 2):S176-80. PubMed ID: 26595736
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy, safety, and tolerance of piperacillin/tazobactam compared to co-amoxiclav plus an aminoglycoside in the treatment of severe pneumonia.
    Speich R; Imhof E; Vogt M; Grossenbacher M; Zimmerli W
    Eur J Clin Microbiol Infect Dis; 1998 May; 17(5):313-7. PubMed ID: 9721959
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Study entry microbiology in patients with acute bacterial exacerbation of chronic bronchitis in a clinical trial stratifying by disease severity.
    Kahn JB; Khashab M; Ambruzs M
    Curr Med Res Opin; 2007 Jan; 23(1):1-7. PubMed ID: 17261234
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of antibiotic treatment in the subset of common-cold patients who have bacteria in nasopharyngeal secretions.
    Kaiser L; Lew D; Hirschel B; Auckenthaler R; Morabia A; Heald A; Benedict P; Terrier F; Wunderli W; Matter L; Germann D; Voegeli J; Stalder H
    Lancet; 1996 Jun; 347(9014):1507-10. PubMed ID: 8684101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.